Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Overcoming the epigenetic and therapeutic barrier of EVI1-overexpressing cancers (EVI1inCancer)

Start date: Jun 1, 2016, End date: May 31, 2021,

Deregulation of the EVI1 oncogene is a key transforming event in the development of many malignancies, most prominently very high-risk acute myeloid leukemia (AML), ovarian, colon, breast, non-small cell lung cancer, and soft-tissue sarcoma. For decades, both EVI1 function and the mechanism underlying its deregulation have been poorly understood. The consequent lack of a targeted therapy against E ...
Read Project

 1

 FINISHED 

Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can ...
Read Project

 13

 FINISHED 

Computational Biophotonics for Endoscopic Cancer Diagnosis and Therapy (COMBIOSCOPY)

Start date: Jul 1, 2015, End date: Jun 30, 2020,

Key challenges in endoscopic tumor diagnosis and therapy consist of the detection and discrimination of malignant tissue as well as the precise navigation of medical instruments. Currently, a low level of sensitivity and specificity in tumor detection and lack of global orientation lead to both over- and undertreatment, tumor recurrence, intra-operative complications, and high costs. The goal of t ...
Read Project

 3

 FINISHED 

Regulating the immune regulators: targeting adaptive immune control (REGiREG)

Start date: Jul 1, 2015, End date: Jun 30, 2020,

The immune system with its complex interactions of cells and molecules needs a very tight and specific interplay of control elements to ensure the establishment and re-establishment of immune homeostasis after challenges. Regulatory T cells (Tregs) are key-players in this regulatory network. It is now well accepted that deficiency or dysfunction of Tregs causes various severe immune disorders due ...
Read Project

 1

 FINISHED 

Dissection of tumor heterogeneity in vivo (CancerHetero)

Start date: Jun 1, 2015, End date: Jun 1, 2020,

It is now widely accepted that tumors are composed of heterogeneous population of cells, which contribute to many aspects of treatment resistance observed in clinic. Despite the acknowledgment of the tumor cell heterogeneity, little evidence was shown about complexity and dynamics of this heterogeneity in vivo, mainly because of lacking flexible genetic tools which allow sophisticated analysis in ...
Read Project

 1

 FINISHED 

Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. (HEP-CAR)

Start date: Jan 1, 2016, End date: Dec 31, 2019,

Hepatocellular carcinoma (HCC) is the most common liver malignancy, with an estimated 750,000 new cases and 695,000 deaths per year, rating third in incidence and mortality in the world. Whilst incidence and mortality for other cancers are declining, HCC represents an increasing public health problem in Europe with men having a higher incidence than women. Several liver diseases lead to HCC and be ...
Read Project

 9

 FINISHED 

Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)

Start date: Jan 1, 2015, End date: Dec 31, 2019,

Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass ...
Read Project

 34

 FINISHED 

Deciphering the machinery involved in stability of the transcription factor HOXA9. (HOXA9 degradome)

Start date: Nov 7, 2016, End date: Nov 6, 2019,

Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor that controls a network of genes critical for hematopoiesis. It shows increased expression levels in more than 50% of patients with acute myeloid leukemia (AML), and is strongly associated with poor clinical outcome. Since the initiation and progression of AML ...
Read Project

 1

 FINISHED 

Coordinated Research Infrastructures Building Enduring Life-science services (CORBEL)

Start date: Sep 1, 2015, End date: Aug 31, 2019,

The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological m ...
Read Project

 39

 FINISHED 

Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)

Start date: Oct 1, 2012, End date: Mar 31, 2019,

ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro ...
Read Project

 7

 FINISHED 

Towards outstanding research and training in tumour biology at IMM (ReTuBi)

Start date: Jan 1, 2016, End date: Dec 31, 2018,

...his goal, IMM is building up a network for outstanding research and innovation with two leading research institutes, the Institut Curie (the largest European cancer research centre), and the DFKZ - Deutsches Krebsforschungszentrum (the largest cancer research institute in Germany), the ReTuBi consortium. ReTuBi targets 4 specific scientific areas: Cancer Stem Cells; Cancer Signalling; Cancer Invas ...
Read Project

 3

 FINISHED 

European Regulatory Science on Tobacco:Policy implementation to reduce lung diseases (EUREST-PLUS)

Start date: Jan 1, 2016, End date: Dec 31, 2018,

Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-related deaths and illness in the EU consist of the Tobacco Products Directive (TPD), and the ongoing implementation of the WHO Framework Convention on Tobacco Control (FCTC). The main objective of EUR ...
Read Project

 13

 FINISHED 

Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells (IMMUNOSHAPE)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. To this end, we have set up a training program in a unique academic-industrial environment that ...
Read Project

 17

 FINISHED 

Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome (EpiPredict)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatm ...
Read Project

 8

 FINISHED 

Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer (CAM-PAC)

Start date: Nov 1, 2013, End date: Oct 31, 2018,

Cancers are genetic disease arising from the accumulation of multiple molecular alterations in affected cells. Large-scale genomic, transcriptomic and proteomic analyses have established comprehensive catalogues of molecules which are altered in their structure and/or abundance in malignant tumors as compared to healthy tissues. Far less developed are concepts and methods to integrate data from di ...
Read Project

 18

 FINISHED 

Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors (REQUITE)

Start date: Oct 1, 2013, End date: Sep 30, 2018,

Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million ...
Read Project

 15

 FINISHED 

implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC (ADOPT BBMRI-ERIC)

Start date: Oct 1, 2015, End date: Sep 30, 2018,

"BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical research. The ADOPT BBMRI-ERIC proposal aims at ...
Read Project

 22

 FINISHED 

Global Mapping of Synthetic Genetic Interactions in Drosophila (SYNGENE)

Start date: Aug 1, 2012, End date: Jul 31, 2018,

The genetics underlying phenotype-genotype relationships during development and disease is often complex with many genes contributing to a particular phenotypic outcome. While forward genetic screens have uncovered many mutations that are limiting at a particular stage or tissue, the majority of genes in most genomes remain genetically untouched. Recent studies in model organisms, in particular in ...
Read Project

 1

 FINISHED 

AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit

Start date: Jul 1, 2016, End date: Jun 30, 2018,

In our 24 months project "AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit", the German Cancer Research Center will grant 32 apprentices the opportunity to partake in an internship as biological laboratory assistants, animal care takers, office clerks and qualified IT specialists. They will all finish the second year of training during the internship and they successfully complet ...
Read Project

 7

 FINISHED 

Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) (NET4CGD)

Start date: Dec 1, 2012, End date: May 31, 2018,

This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several member ...
Read Project

 11

 FINISHED 

Deciphering the regulatory T cell repertoire: towards biomarkers and biotherapies for autoimmune diseases (TRIPOD)

Start date: May 1, 2013, End date: Apr 30, 2018,

The discovery of regulatory T cells (Tregs) is a breakthrough in immunology: it revolutionises our understanding of autoimmune disease (AID) pathophysiology and treatment opportunities. Treg numbers or function is defective in most mouse and human AIDs and their restoration induces clinical improvement, as we recently showed using low-dose IL-2 to induce Tregs in patients with AID.The TRiPoD proje ...
Read Project

 2

 FINISHED 

Mechanisms of Mismatch repair inactivation and identification of genes suppressing mutations (iMMR)

Start date: Apr 1, 2014, End date: Mar 31, 2018,

The fidelity of DNA replication, and therefore the stability of the genome, relies on the DNA Mismatch repair (MMR) pathway, which recognizes DNA replication errors and promotes repair by an excision and re-synthesis mechanism. Mutations that inactivate MMR are associated to Lynch Syndrome, an early-onset cancer disorder characterized by accumulation of mutations at repetitive sequences or microsa ...
Read Project

 1

 FINISHED 

Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse (MADCIN)

Start date: Feb 1, 2012, End date: Jan 31, 2018,

Chromosomal instability (CIN), the inability to correctly segregate sister chromatids during mitosis, is a hallmark of cancer cells. Overexpression of the mitotic checkpoint protein Mad2, commonly found in human tumors, leads to CIN and the development of aneuploid tumors in mouse models. However, recent observations from various laboratories suggest that aneuploidy can promote or suppress tumorig ...
Read Project

 2

 FINISHED 

PIVOTAL ASSESSMENT OF THE EFFECTS OF BIOACTIVES ON HEALTH AND WELLBEING. FROM HUMAN GENOMA TO FOOD INDUSTRY - PATHWAY (PATHWAY-27)

Start date: Feb 1, 2013, End date: Jan 31, 2018,

Scientific understanding of the role and mechanisms of bioactives is fragmented. Research often addresses the theoretical possibility of health improvement effects rather than their real, practical use for everyday diets. Bioactives cannot be considered as discrete chemical compounds and research must focus on bioactive-enriched foods (BEF), if consumer demands for foods delivering appropriate hea ...
Read Project

 28

 FINISHED 

Early warning signals of ageing in human stem cells and age-related disorders (SYSTEMAGE)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. Whereas the vulnerability to cancer and chronic inflammation is associated with a decline of the immune system, the latter is in turn a sum product of interactions among hematopoietic stem cells (HSC), endothelial ...
Read Project

 11

 FINISHED 

Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)

Start date: Jan 1, 2013, End date: Dec 31, 2017,

Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased inciden ...
Read Project

 13

 FINISHED 

Generating self-antigen diversity in the thymus: from gene expression patterns in single cells to the system level, an integrative approach (SELF-TOLERANCE)

Start date: Jun 1, 2012, End date: Nov 30, 2017,

The thymus plays a central role in the induction of self-tolerance, a hallmark of the immune system. During T cell development a highly diverse T cell receptor repertoire is probed against a matching array of self-antigens. While the generation of the T cell receptor repertoire relies on unique genetic recombination mechanisms, the corresponding molecular principles underlying the generation of TC ...
Read Project

 1

 FINISHED 

Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)

Start date: Dec 1, 2012, End date: Nov 30, 2017,

Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillat ...
Read Project

 13

 FINISHED 

Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun ...
Read Project

 11

 FINISHED 

The impact of chromosomal instability on health: Molecular causes and consequences of aneuploidy (PLOIDYNET)

Start date: Oct 1, 2013, End date: Sep 30, 2017,

Aneuploidy, an abnormal number of chromosomes, is a hallmark of cancer cells, affecting the majority of all human tumours. Aneuploidy arises when errors occur during mitosis, as the duplicated chromosomes are distributed between the two new daughter cells. Paradoxically, aneuploidy appears to have detrimental consequences for the physiology of untransformed cells in vitro, inhibiting rather than s ...
Read Project

 14

 FINISHED 

T-cell based immunotherapy in pancreatic cancer - basic concepts and pre-clinical development (TIPC_TIL_IP)

Start date: Sep 1, 2013, End date: Aug 31, 2017,

"Pancreatic ductal adenocarcinoma (PDA) has a devastating prognosis and novel treatment approaches are urgently needed. T cell-based immunotherapy making use of in vitro expanded tumor-infiltrating lymphocytes (TIL) has recently emerged as a potent therapy in melanoma, with the potential to cure even patients with advanced disease.We are currently working towards the development of TIL therapy for ...
Read Project

 1

 FINISHED 

Quantitative T cell Immunology (QuanTI)

Start date: May 1, 2013, End date: Apr 30, 2017,

The primary objective of this ITN is to train a new generation of European quantitative immunologists, who will be able to address challenges arising in Systems Immunology. This will be achieved with the proposed Network, Quantitative T cell Immunology (QuanTI), that will train 11 ESRs and 4 ERs, bringing together renowned experimental and theoretical scientists from private and academic instituti ...
Read Project

 12

 FINISHED 

Unlocking the potential of ultra-high-field MRI through manipulation of radiofrequency excitation fields in human tissue (MRexcite)

Start date: May 1, 2012, End date: Apr 30, 2017,

In the past three decades, magnetic resonance imaging (MRI) has become a vital tool for clinical diagnosis and research. A major current trend is the introduction of magnets with much more powerful static magnetic fields, including magnets at 7 Tesla (7T) and higher. Advantages of higher magnetic fields include higher signal-to-noise ratios enabling improved spatial and temporal resolution, and ne ...
Read Project

 2

 FINISHED 

Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)

Start date: Feb 1, 2012, End date: Jan 31, 2017,

The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys ...
Read Project

 29

 FINISHED 

A European Platform for Translational Cancer Research (EUROCANPLATFORM)

Start date: Jan 1, 2011, End date: Dec 31, 2016,

Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in ...
Read Project

 29

 FINISHED 

The RANK-Axis in Breast Cancer: A comprehensive prospective evaluation of promising novel biomarkers (RANKL_OPG)

Start date: Jan 1, 2015, End date: Dec 31, 2016,

"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality in women worldwide. The recently identified Receptor Activator of Nuclear Factor (NF)-κB (RANK)-axis has stimulated novel research in the field of breast cancer etiology, treatment, and prevention. Experimental data implicate RANK signalling in mammary tumor development. Preliminary human data show inc ...
Read Project

 1

 FINISHED 

Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)

Start date: May 1, 2013, End date: Oct 31, 2016,

Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl ...
Read Project

 5

 FINISHED 

Identifying and characterising transmembrane transporters of tryptophan and kynurenine in normal and cancerous brain tissue (KP Transport)

Start date: Sep 1, 2014, End date: Aug 31, 2016,

The catabolism of the essential amino acid tryptophan (Trp) by tumour cells expressing either IDO1/2 or TDO has been associated with malignant tumour progression and poor patient survival. Expression of these rate-limiting genes leads to both depletion of Trp and accumulation of the Trp breakdown product kynurenine (Kyn) in the tumour microenvironment. Kyn has recently been shown to act as a lig ...
Read Project

 1

 FINISHED 

AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit

Start date: Jul 1, 2014, End date: Jun 30, 2016,

In our 24 months project "AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit", 21 apprentices, 1 animal keeper who completed his training in 2015 and 3 staff members of the training department had the opportunity to partake. Most of the participants are completing an apprenticeship as biological laboratory assistants (17), office clerks (3) and qualified IT specialists (1). They al ...
Read Project

 7

 FINISHED 

ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)

Start date: Nov 1, 2010, End date: Apr 30, 2016,

Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact ...
Read Project

 20